DBV Technologies (NASDAQ:DBVT - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
Several other equities research analysts also recently issued reports on the company. Zacks Research raised DBV Technologies from a "strong sell" rating to a "hold" rating in a report on Monday, September 29th. JMP Securities restated a "market outperform" rating and issued a $21.00 price objective on shares of DBV Technologies in a research note on Thursday, June 26th. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Finally, Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, DBV Technologies presently has an average rating of "Hold" and an average target price of $14.75.
View Our Latest Stock Analysis on DBV Technologies
DBV Technologies Trading Up 11.5%
DBVT stock traded up $1.64 during midday trading on Wednesday, hitting $15.88. The stock had a trading volume of 215,955 shares, compared to its average volume of 92,533. The firm has a market capitalization of $435.11 million, a price-to-earnings ratio of -3.33 and a beta of -0.45. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $15.96. The stock has a 50-day simple moving average of $9.96 and a 200 day simple moving average of $9.25.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $0.64 million. On average, equities analysts forecast that DBV Technologies will post -7.05 EPS for the current year.
Institutional Investors Weigh In On DBV Technologies
Several hedge funds have recently added to or reduced their stakes in DBVT. Vivo Capital LLC purchased a new position in shares of DBV Technologies in the second quarter worth $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies during the second quarter valued at $9,659,000. MPM Bioimpact LLC purchased a new stake in DBV Technologies during the second quarter valued at $9,649,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the second quarter worth about $9,315,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies in the second quarter worth about $340,000. 71.74% of the stock is owned by institutional investors.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.